Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). (Q42174751)

18 October 2017

Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). (English)

1 reference

18 October 2017

1 reference

Tyndale RF

1

1 reference

18 October 2017

Kalow W

series ordinal

2

1 reference

18 October 2017

Inaba T

series ordinal

3

1 reference

18 October 2017

language of work or name

English

0 references

publication date

1 June 1991

1 reference

British Journal of Clinical Pharmacology

18 October 2017

1 reference

18 October 2017

31

1 reference

18 October 2017

6

1 reference

18 October 2017

655-660

1 reference

Sparteine metabolism in Canadian Caucasians

18 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in guinea pigs

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Inhibitory effects of neuroleptics on debrisoquine oxidation in man

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Substantial rise in sparteine metabolic ratio during haloperidol treatment

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Interconversions of haloperidol and reduced haloperidol in guinea pig and rat liver microsomes

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Rapid formation of reduced haloperidol in guinea pigs following haloperidol administration.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Haloperidol and metabolite concentrations in the rat after concurrent isotretinoin administration: a preliminary report.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Concurrent lithium administration results in higher haloperidol levels in brain and plasma of guinea pigs.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Metabolism of diazepam in vitro by human liver. Independent variability of N-demethylation and C3-hydroxylation.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Dopamine D1 receptors of the calf parathyroid gland: identification and characterization.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Interconversion between haloperidol and reduced haloperidol in healthy volunteers

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Reduced haloperidol/haloperidol ratios in plasma: polymorphism in Japanese psychiatric patients.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Isolation and Identification of a Metabolite of Haloperidol

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Reduced haloperidol: Effects on striatal dopamine metabolism and conversion to haloperidol in the rat

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs

17 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.1991.TB05588.X

Debrisoquine oxidation in schizophrenic patients treated with neuroleptics

21 January 2018

2 references

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.1991.TB05588.X

21 January 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368575

Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism

3 November 2018

1 reference

12 December 2020

Interconversion between haloperidol and reduced haloperidol in humans

1 reference

12 December 2020

Low plasma reduced haloperidol/haloperidol ratios in Chinese patients

1 reference

12 December 2020

Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol

1 reference

12 December 2020

Sparteine metabolism capacity in human liver: structural variants of human P450IID6 as assessed by immunochemistry

1 reference

12 December 2020

Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs

1 reference

12 December 2020

Reduced haloperidol in the post-mortem brains of haloperidol-treated patients

1 reference

12 December 2020

Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients

1 reference

12 December 2020

In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine

1 reference

12 December 2020

Simultaneous determination of haloperidol and reduced haloperidol by gas chromatography using a megabore column with electron-capture detection: application to microsomal oxidation of reduced haloperidol

1 reference

12 December 2020

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

1 reference

12 December 2020

Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)

1 reference

12 December 2020

Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man

1 reference

12 December 2020

Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitro

1 reference

12 December 2020

Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes

1 reference

12 December 2020

In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase

1 reference

12 December 2020

Debrisoquine oxidative phenotyping and psychiatric drug treatment

1 reference

12 December 2020

Haloperidol reductase in human and guinea pig livers

1 reference

12 December 2020

Haloperidol reduction can be assayed in human red blood cells

1 reference

12 December 2020

Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings

1 reference

12 December 2020

Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol

1 reference

12 December 2020

Inhibition of desipramine 2-hydroxylation by quinidine and quinine

1 reference

12 December 2020

10.1111/J.1365-2125.1991.TB05588.X

Identifiers

DOI

1 reference

18 October 2017

1 reference

18 October 2017

1 reference